Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma. The TASMA Randomized Trial

Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT, but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates fo...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine Vol. 203; no. 2; p. 175
Main Authors: Goorsenberg, Annika W M, d'Hooghe, Julia N S, Srikanthan, Karthikan, Ten Hacken, Nick H T, Weersink, Els J M, Roelofs, Joris J T H, Kemp, Samuel V, Bel, Elisabeth H, Shah, Pallav L, Annema, Jouke T, Bonta, Peter I
Format: Journal Article
Language:English
Published: United States 15.01.2021
Subjects:
ISSN:1535-4970, 1535-4970
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT, but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates for BT treatment is important. First, to assess the effect of BT on ASM mass, and second, to identify patient characteristics that correlate with BT response. Patients with severe asthma (  = 40) were randomized to immediate (  = 20) or delayed (  = 20) BT treatment. Before randomization, clinical, functional, blood, and airway biopsy data were collected. In the delayed control group, reassessment, including biopsies, was performed after 6 months of standard clinical care, followed by BT. In both groups, post-BT data including biopsies were obtained after 6 months. ASM mass (% positive desmin or α-smooth muscle actin area in the total biopsy) was calculated with automated digital analysis software. Associations between baseline characteristics and Asthma Control Questionnaire and Asthma Quality of Life Questionnaire (AQLQ) improvement were explored. Median ASM mass decreased by >50% in the immediate BT group (  = 17) versus no change in the delayed control group (  = 19) (  = 0.0004). In the immediate group, Asthma Control Questionnaire scores improved with -0.79 (interquartile range [IQR], -1.61 to 0.02) compared with 0.09 (IQR, -0.25 to 1.17) in the delayed group (  = 0.006). AQLQ scores improved with 0.83 (IQR, -0.15 to 1.69) versus -0.02 (IQR, -0.77 to 0.75) (  = 0.04). Treatment response in the total group (  = 35) was positively associated with serum IgE and eosinophils but not with baseline ASM mass. ASM mass significantly decreases after BT when compared with a randomized non-BT-treated control group. Treatment response was associated with serum IgE and eosinophil levels but not with ASM mass.
AbstractList Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT, but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates for BT treatment is important. First, to assess the effect of BT on ASM mass, and second, to identify patient characteristics that correlate with BT response. Patients with severe asthma (  = 40) were randomized to immediate (  = 20) or delayed (  = 20) BT treatment. Before randomization, clinical, functional, blood, and airway biopsy data were collected. In the delayed control group, reassessment, including biopsies, was performed after 6 months of standard clinical care, followed by BT. In both groups, post-BT data including biopsies were obtained after 6 months. ASM mass (% positive desmin or α-smooth muscle actin area in the total biopsy) was calculated with automated digital analysis software. Associations between baseline characteristics and Asthma Control Questionnaire and Asthma Quality of Life Questionnaire (AQLQ) improvement were explored. Median ASM mass decreased by >50% in the immediate BT group (  = 17) versus no change in the delayed control group (  = 19) (  = 0.0004). In the immediate group, Asthma Control Questionnaire scores improved with -0.79 (interquartile range [IQR], -1.61 to 0.02) compared with 0.09 (IQR, -0.25 to 1.17) in the delayed group (  = 0.006). AQLQ scores improved with 0.83 (IQR, -0.15 to 1.69) versus -0.02 (IQR, -0.77 to 0.75) (  = 0.04). Treatment response in the total group (  = 35) was positively associated with serum IgE and eosinophils but not with baseline ASM mass. ASM mass significantly decreases after BT when compared with a randomized non-BT-treated control group. Treatment response was associated with serum IgE and eosinophil levels but not with ASM mass.
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT, but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates for BT treatment is important.Objectives: First, to assess the effect of BT on ASM mass, and second, to identify patient characteristics that correlate with BT response.Methods: Patients with severe asthma (n = 40) were randomized to immediate (n = 20) or delayed (n = 20) BT treatment. Before randomization, clinical, functional, blood, and airway biopsy data were collected. In the delayed control group, reassessment, including biopsies, was performed after 6 months of standard clinical care, followed by BT. In both groups, post-BT data including biopsies were obtained after 6 months. ASM mass (% positive desmin or α-smooth muscle actin area in the total biopsy) was calculated with automated digital analysis software. Associations between baseline characteristics and Asthma Control Questionnaire and Asthma Quality of Life Questionnaire (AQLQ) improvement were explored.Measurements and Main Results: Median ASM mass decreased by >50% in the immediate BT group (n = 17) versus no change in the delayed control group (n = 19) (P = 0.0004). In the immediate group, Asthma Control Questionnaire scores improved with -0.79 (interquartile range [IQR], -1.61 to 0.02) compared with 0.09 (IQR, -0.25 to 1.17) in the delayed group (P = 0.006). AQLQ scores improved with 0.83 (IQR, -0.15 to 1.69) versus -0.02 (IQR, -0.77 to 0.75) (P = 0.04). Treatment response in the total group (n = 35) was positively associated with serum IgE and eosinophils but not with baseline ASM mass.Conclusions: ASM mass significantly decreases after BT when compared with a randomized non-BT-treated control group. Treatment response was associated with serum IgE and eosinophil levels but not with ASM mass.Rationale: Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT, but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates for BT treatment is important.Objectives: First, to assess the effect of BT on ASM mass, and second, to identify patient characteristics that correlate with BT response.Methods: Patients with severe asthma (n = 40) were randomized to immediate (n = 20) or delayed (n = 20) BT treatment. Before randomization, clinical, functional, blood, and airway biopsy data were collected. In the delayed control group, reassessment, including biopsies, was performed after 6 months of standard clinical care, followed by BT. In both groups, post-BT data including biopsies were obtained after 6 months. ASM mass (% positive desmin or α-smooth muscle actin area in the total biopsy) was calculated with automated digital analysis software. Associations between baseline characteristics and Asthma Control Questionnaire and Asthma Quality of Life Questionnaire (AQLQ) improvement were explored.Measurements and Main Results: Median ASM mass decreased by >50% in the immediate BT group (n = 17) versus no change in the delayed control group (n = 19) (P = 0.0004). In the immediate group, Asthma Control Questionnaire scores improved with -0.79 (interquartile range [IQR], -1.61 to 0.02) compared with 0.09 (IQR, -0.25 to 1.17) in the delayed group (P = 0.006). AQLQ scores improved with 0.83 (IQR, -0.15 to 1.69) versus -0.02 (IQR, -0.77 to 0.75) (P = 0.04). Treatment response in the total group (n = 35) was positively associated with serum IgE and eosinophils but not with baseline ASM mass.Conclusions: ASM mass significantly decreases after BT when compared with a randomized non-BT-treated control group. Treatment response was associated with serum IgE and eosinophil levels but not with ASM mass.
Author Weersink, Els J M
Srikanthan, Karthikan
Ten Hacken, Nick H T
d'Hooghe, Julia N S
Roelofs, Joris J T H
Goorsenberg, Annika W M
Shah, Pallav L
Kemp, Samuel V
Bonta, Peter I
Bel, Elisabeth H
Annema, Jouke T
Author_xml – sequence: 1
  givenname: Annika W M
  surname: Goorsenberg
  fullname: Goorsenberg, Annika W M
  organization: Department of Respiratory Medicine and
– sequence: 2
  givenname: Julia N S
  surname: d'Hooghe
  fullname: d'Hooghe, Julia N S
  organization: Department of Respiratory Medicine and
– sequence: 3
  givenname: Karthikan
  surname: Srikanthan
  fullname: Srikanthan, Karthikan
  organization: Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
– sequence: 4
  givenname: Nick H T
  surname: Ten Hacken
  fullname: Ten Hacken, Nick H T
  organization: Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
– sequence: 5
  givenname: Els J M
  surname: Weersink
  fullname: Weersink, Els J M
  organization: Department of Respiratory Medicine and
– sequence: 6
  givenname: Joris J T H
  surname: Roelofs
  fullname: Roelofs, Joris J T H
  organization: Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
– sequence: 7
  givenname: Samuel V
  surname: Kemp
  fullname: Kemp, Samuel V
  organization: National Heart & Lung Institute, Imperial College, London, United Kingdom; and
– sequence: 8
  givenname: Elisabeth H
  surname: Bel
  fullname: Bel, Elisabeth H
  organization: Department of Respiratory Medicine and
– sequence: 9
  givenname: Pallav L
  orcidid: 0000-0002-9052-4638
  surname: Shah
  fullname: Shah, Pallav L
  organization: Department of Pulmonology, Chelsea & Westminster Hospital, London, United Kingdom
– sequence: 10
  givenname: Jouke T
  surname: Annema
  fullname: Annema, Jouke T
  organization: Department of Respiratory Medicine and
– sequence: 11
  givenname: Peter I
  surname: Bonta
  fullname: Bonta, Peter I
  organization: Department of Respiratory Medicine and
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32721210$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtKAzEUhoNUrK2-gAvJ0s3U3Oa2HIuXQkuhnf2QJmdoZCapyYxSVz66I1ZwdQ6c7_8O_BM0ss4CQjeUzChNxL1Xqp0xQnNKI8bybD0_Q5c05nEk8pSM_u1jNAnhlRDKMkou0JizlFFGySX6evDOqr2RDS734Ft3aGTojnhhda9A48L4D3nE29a5bo9XfVAN4A0Mx844i6XVeN4Ya9Qg2EA4OBsAG4u38A4ecBG6fStnP25cFttVgTdDxLXmc3CXfnh7hc5r2QS4Ps0pKp8ey_lLtFw_L-bFMlJC0C5SWies1jLOgBCtZS4U45Lwmot6l4CqNaSK01QkiUgl5SkFnrNdnSsNkjM2RXe_2oN3bz2ErmpNUNA00oLrQ8UEy-JYZCwb0NsT2u9a0NXBm1b6Y_VXGvsG5lRy3A
CitedBy_id crossref_primary_10_1016_j_heliyon_2023_e20797
crossref_primary_10_1007_s41030_022_00208_6
crossref_primary_10_2147_JAA_S492730
crossref_primary_10_1177_17534666241266348
crossref_primary_10_1186_s13223_023_00796_1
crossref_primary_10_1136_thorax_2023_220967
crossref_primary_10_1183_23120541_00116_2022
crossref_primary_10_1139_cjpp_2024_0277
crossref_primary_10_1183_13993003_01397_2023
crossref_primary_10_3390_jpm12050850
crossref_primary_10_2147_JAA_S280247
crossref_primary_10_1001_jama_2020_16895
crossref_primary_10_1111_resp_14248
crossref_primary_10_1016_j_rmed_2024_107583
crossref_primary_10_1183_23120541_00024_2023
crossref_primary_10_1097_MCP_0000000000000840
crossref_primary_10_1016_j_rmr_2022_08_009
crossref_primary_10_1097_MCP_0000000000000927
crossref_primary_10_1016_j_pupt_2024_102329
crossref_primary_10_1016_j_jaip_2023_04_036
crossref_primary_10_2147_JAA_S383418
crossref_primary_10_1016_j_pccm_2025_05_001
crossref_primary_10_1183_13993003_01565_2021
crossref_primary_10_1007_s40521_023_00341_w
crossref_primary_10_2147_JAA_S357037
crossref_primary_10_1183_23120541_00268_2021
crossref_primary_10_1016_j_arbres_2024_09_007
crossref_primary_10_1016_j_chest_2021_10_044
crossref_primary_10_1183_13993003_00622_2021
crossref_primary_10_1016_j_jaci_2021_03_035
crossref_primary_10_2147_JAA_S320817
crossref_primary_10_1111_resp_14312
crossref_primary_10_1016_j_chest_2023_12_015
crossref_primary_10_2147_JAA_S404254
crossref_primary_10_1016_j_mcna_2022_08_004
crossref_primary_10_1016_j_jaci_2021_02_024
crossref_primary_10_1080_20009666_2021_1936951
crossref_primary_10_1136_bmjresp_2023_001628
crossref_primary_10_3390_jpm12071093
crossref_primary_10_1080_02770903_2024_2309532
crossref_primary_10_3390_jpm12010010
crossref_primary_10_1111_cea_70071
crossref_primary_10_1016_j_rmed_2023_107340
crossref_primary_10_1183_23120541_00690_2021
crossref_primary_10_1080_02770903_2023_2297375
crossref_primary_10_1039_D4RA03585B
crossref_primary_10_1136_bmjresp_2022_001351
crossref_primary_10_1055_a_1370_2409
crossref_primary_10_1016_j_rmr_2021_01_002
crossref_primary_10_1016_j_chest_2021_03_042
crossref_primary_10_1016_j_jaci_2023_09_035
crossref_primary_10_3390_app13042694
crossref_primary_10_1016_j_rmed_2023_107302
crossref_primary_10_1164_rccm_202008_3173ED
crossref_primary_10_1016_j_rmed_2023_107303
crossref_primary_10_1183_13993003_02018_2021
ContentType Journal Article
Contributor Dirksen, T
Augustijn, S
Caneja, C
Lone-Latif, S
van de Pol, M
de Boer, O
Hartman, J
Contributor_xml – sequence: 1
  givenname: C
  surname: Caneja
  fullname: Caneja, C
– sequence: 2
  givenname: J
  surname: Hartman
  fullname: Hartman, J
– sequence: 3
  givenname: S
  surname: Augustijn
  fullname: Augustijn, S
– sequence: 4
  givenname: M
  surname: van de Pol
  fullname: van de Pol, M
– sequence: 5
  givenname: S
  surname: Lone-Latif
  fullname: Lone-Latif, S
– sequence: 6
  givenname: O
  surname: de Boer
  fullname: de Boer, O
– sequence: 7
  givenname: T
  surname: Dirksen
  fullname: Dirksen, T
CorporateAuthor TASMA research group
CorporateAuthor_xml – name: TASMA research group
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1164/rccm.201911-2298OC
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1535-4970
ExternalDocumentID 32721210
Genre Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
0R~
23M
2WC
34G
39C
53G
5GY
5RE
7RV
7X7
8C1
8FW
8R4
8R5
AAQQT
AAWTL
ABJNI
ABOCM
ABPMR
ACGFO
ACGFS
ADBBV
AENEX
AFCHL
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
BPHCQ
C45
CGR
CS3
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
EJD
EMOBN
EX3
F5P
FRP
GX1
H13
HZ~
IH2
J5H
KQ8
L7B
M5~
NPM
O9-
OBH
OFXIZ
OGEVE
OK1
OVD
OVIDX
P2P
PCD
PQQKQ
Q2X
RWL
SJN
TAE
TEORI
THO
TR2
W8F
WH7
WOQ
WOW
X7M
YJK
~02
7X8
ID FETCH-LOGICAL-c441t-cdd62fda58e00dda94c23a03f34fb6ecfde7c31746647a1371e392bf9cdea322
IEDL.DBID 7X8
ISICitedReferencesCount 66
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000611394400012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1535-4970
IngestDate Thu Sep 04 17:17:53 EDT 2025
Thu Apr 03 06:50:53 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords airway smooth muscle
severe asthma
bronchial thermoplasty
airway remodeling
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c441t-cdd62fda58e00dda94c23a03f34fb6ecfde7c31746647a1371e392bf9cdea322
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-9052-4638
OpenAccessLink https://pure.rug.nl/ws/files/168049003/Bronchial_Thermoplasty_Induced_Airway_Smooth_Muscle_Reduction_and_Clinical_Response_in_Severe_Asthma.pdf
PMID 32721210
PQID 2428554828
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2428554828
pubmed_primary_32721210
PublicationCentury 2000
PublicationDate 2021-01-15
20210115
PublicationDateYYYYMMDD 2021-01-15
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of respiratory and critical care medicine
PublicationTitleAlternate Am J Respir Crit Care Med
PublicationYear 2021
References 32841571 - Am J Respir Crit Care Med. 2021 Jan 15;203(2):153-154
32990450 - Am J Respir Crit Care Med. 2021 Jan 1;203(1):148
32990451 - Am J Respir Crit Care Med. 2021 Jan 1;203(1):148-149
References_xml – reference: 32990450 - Am J Respir Crit Care Med. 2021 Jan 1;203(1):148
– reference: 32841571 - Am J Respir Crit Care Med. 2021 Jan 15;203(2):153-154
– reference: 32990451 - Am J Respir Crit Care Med. 2021 Jan 1;203(1):148-149
SSID ssj0012810
Score 2.571599
Snippet Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass...
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 175
SubjectTerms Adolescent
Adult
Aged
Airway Remodeling
Asthma - diagnosis
Asthma - pathology
Asthma - physiopathology
Asthma - surgery
Biopsy
Bronchi - pathology
Bronchi - surgery
Bronchial Thermoplasty
Bronchoscopy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Muscle, Smooth - pathology
Muscle, Smooth - surgery
Severity of Illness Index
Treatment Outcome
Young Adult
Title Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma. The TASMA Randomized Trial
URI https://www.ncbi.nlm.nih.gov/pubmed/32721210
https://www.proquest.com/docview/2428554828
Volume 203
WOSCitedRecordID wos000611394400012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvAam-wmTXKSUCxeUkvbQ29lsw8stEltWqWe_OnOJCk9CYKXHAI7CTvfvHZmZwh5CB0FVhfkG7SfxtMq30oSblvGBIy7zHAjRDFswu90guEw7FYHbnlVVrnWiYWiVpnEM_IGmBKsqIIA4Wn2buHUKMyuViM0tkmNgyuDqPaHmywCC8puBB73cJKavb4003QbcynxHjpEK47FWBi8tn53MQtT0z78708ekYPKyaRRiYpjsqXTE7IXV2n0U_INwXeKRc4TCjCZT7MZ-NCLFcU5HlIrGo3nn2JF-9MM-EjjZQ5UaA-bvCIbqUgVrfqJTuB1UWSr6TilfQ2CoWmUL96m4hFp00HUjyPagyXZdPwFtAeI-DMyaD8PWi9WNYrBkuAvLSypVJMZJbxA27ZSInQl48LmhrsmaWpplPYluCLYrN4XDvcdDRBITCiVFqAzzslOmqX6klDtcukZ2w-DBPRH6Aj4ADOewTIR4UheJ_frrR0B0jF9IVKdLfPRZnPr5KLkz2hWtuQYcQaRLEDu6g-rr8k-w8IU27Ec74bUDMi5viW78mMxzud3BYTg2enGPwxW0Tw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bronchial+Thermoplasty+Induced+Airway+Smooth+Muscle+Reduction+and+Clinical+Response+in+Severe+Asthma.+The+TASMA+Randomized+Trial&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=Goorsenberg%2C+Annika+W+M&rft.au=d%27Hooghe%2C+Julia+N+S&rft.au=Srikanthan%2C+Karthikan&rft.au=Ten+Hacken%2C+Nick+H+T&rft.date=2021-01-15&rft.eissn=1535-4970&rft.volume=203&rft.issue=2&rft.spage=175&rft_id=info:doi/10.1164%2Frccm.201911-2298OC&rft_id=info%3Apmid%2F32721210&rft_id=info%3Apmid%2F32721210&rft.externalDocID=32721210
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-4970&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-4970&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-4970&client=summon